Damania Lab finds target in metabolic pathway for non-Hodgkin lymphoma

Researchers in the Department of Microbiology & Immunology have identified possible targets in the PI3K/AKT/mTOR metabolic pathway that could be used in the fight against non-Hodgkin lymphoma...

Researchers in the Department of Microbiology & Immunology have identified possible targets in the PI3K/AKT/mTOR metabolic pathway that could be used in the fight against non-Hodgkin lymphoma. In a paper recently published in PNAS, Blossom Damania's group has discovered that B cell lymphoma cells are much more sensitive to drugs that inhibit fatty acid synthesis than normal B cells. They speculate that these metabolically dysregulated cancer cells may be due to viral infection (possibly with Epstein-Barr virus or Kaposi's sarcoma herpesvirus). M&I graduate student Aadra Bhatt was the first author of this paper. For more information on this research, click here.